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Human Gyrovirus Apoptin shows a similar subcellular
distribution pattern and apoptosis induction as the
chicken anaemia virus derived VP3/Apoptin
J Bullenkamp1,3, D Cole1,3, F Malik2, H Alkhatabi2, A Kulasekararaj2, EW Odell1, F Farzaneh2, J Ga¨ken2,3 and M Tavassoli*,1,3
The chicken anaemia virus-derived protein Apoptin/VP3 (CAV-Apoptin) has the important ability to induce tumour-selective
apoptosis in a variety of human cancer cells. Recently the first human Gyrovirus (HGyV) was isolated from a human skin swab. It
shows significant structural and organisational resemblance to CAV and encodes a homologue of CAV-Apoptin/VP3. Using
overlapping primers we constructed a synthetic human Gyrovirus Apoptin (HGyV-Apoptin) fused to green fluorescent protein in
order to compare its apoptotic function in various human cancer cell lines to CAV-Apoptin. HGyV-Apoptin displayed a similar
subcellular expression pattern as observed for CAV-Apoptin, marked by translocation to the nucleus of cancer cells, although it
is predominantly located in the cytosol of normal human cells. Furthermore, expression of either HGyV-Apoptin or CAV-Apoptin
in several cancer cell lines triggered apoptosis at comparable levels. These findings indicate a potential anti-cancer role for
HGyV-Apoptin.
Cell Death and Disease (2012) 3, e296; doi:10.1038/cddis.2012.34; published online 12 April 2012
Subject Category: Cancer
Apoptin was originally identified as the death-inducing protein
VP3 from chicken anaemia virus (CAV), the first member of
the Gyrovirus genus. Infection with the virus, which is mainly
transmitted through contaminated feathers, has been shown
to trigger apoptosis in thymocytes and myeloid progenitor
cells of young chicken.1 CAV is a single-stranded DNA virus
which encodes three proteins, VP1 (capsid protein), VP2
(protein phosphatase and scaffold protein) and VP3.2 In vitro,
expression of VP3 alone induces apoptosis of chicken lympho-
blastoid T-cells and myeloid cells in a similar way as observed
after CAV infection.3,4 Hence, VP3 was renamed Apoptin.
CAV-Apoptin is a 121 amino-acid protein rich in proline,
serine, threonine and basic amino acids.5,6 It contains a
bipartite-type nuclear localisation signal (NLS1 and NLS2) at
position 82-88 and 111-121 and a nuclear export signal (NES)
suggesting potential shuttling of the protein between nucleus
and cytoplasm.7,8 Both predicted NLSs of Apoptin are
required for its efficient nuclear localisation.7 Furthermore,
Apoptin contains several potential phosphorylation sites,
including threonine 108.9
Importantly, Apoptin has the ability to induce apoptosis in
various human cancer cells but not in normal cells.10–12 It
triggers apoptosis through the intrinsic mitochondrial pathway
requiring caspase-3 and caspase-9, but not caspase-8. Cell
death is induced independently of p53 but possibly involves
the p53 family member p73 that can transactivate pro-
apoptotic targets such as Bax and Puma.13,14 Furthermore,
the sphingomyelin-ceramide pathway has been shown to
have a role in Apoptin-induced cytotoxicity.15 However, the
precise cellular mechanisms of Apoptin-induced cell death
and the mode of tumour selectivity remain unclear. There are
distinct differences regarding Apoptin expression between
normal and tumour cells, which may provide clues about the
mechanisms of tumour cell sensitivity to Apoptin. Firstly, in
tumour cells Apoptin localises to the nucleus, which is
important for its ability to induce apoptosis, whereas in normal
cells it is predominantly expressed in the cytoplasm.10,16 In
addition, Apoptin is phosphorylated on threonine 108 in
tumour but not in normal cells, which drives nuclear
accumulation in tumour cells.9 The specific kinase/s respon-
sible for Apoptin phosphorylation remain unidentified. How-
ever, several kinases, including PKCb and CDK2 have been
shown to phosphorylate Apoptin.17,18
Recently, a virus showing significant homology to CAV was
isolated from skin swabs of healthy volunteers and designated
human Gyrovirus or HGyV.19 Similar to CAV the HGyV
genome consists of a single-stranded negative-sense circular
DNA of 2.315 nucleotides (compared with 2.290–2.320 for
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CAV), containing three partially overlapping open reading
frames. Alignment with CAV revealed relatively low overall
sequence identity with a maximal identity of 70% in the region
of nucleotides 100–700 but a similar organisation of the
promoter region and the encoded proteins. In addition to VP1
and VP2 HGyV encodes a slightly larger, 125 amino-acid
homologue of CAV-Apoptin/VP3 (121 amino acids for
comparison). Despite a low overall identity important regions
such as the nuclear localisation and export signals and
phosphorylation sites are conserved between HGyV- and
CAV-Apoptin. The effects or involvement of this novel virus in
human disease and the functional properties of human
Gyrovirus Apoptin (HGyV-Apoptin) are currently unknown.
To investigate whether HGyV-Apoptin has apoptotic and
tumour selective activity similar to its homologue CAV-
Apoptin we developed a synthetic HGyV-Apoptin fused to
green fluorescent protein (GFP). Expression of this construct
in human cancer cell lines revealed a subcellular localisation
and pro-apoptotic function comparable to CAV-Apoptin.
Results
Expression of HGyV-Apoptin in human cancer cells. To
test the expression of the newly generated HGyV-Apoptin
constructs, HCT116 colon carcinoma and Saos-2 osteosar-
coma cells were transfected with the corresponding plasmids
pHGyV-GFP-AP and pHGyV-FLAG-AP. Western blot analy-
sis of transfected cells after 2 days revealed expression of
both HGyV-GFP-AP and HGyV-FLAG-AP that could be
detected at the estimated molecular weights (Figures 1a
and b). Compared with its CAV homologue HGyV-GFP-AP
is slightly larger as expected from the difference in length.
Re-probing with a CAV-Apoptin phospho-specific antibody
directed against phosphorylated threonine 108 did not reveal
any cross-reaction with HGyV-Apoptin (data not shown).
HGyV-Apoptin translocates to the nucleus and induces
changes in nuclear morphology in cancer cells. CAV-
Apoptin is known to translocate to the nucleus in transformed
cells which is at least partially important for the induction of
apoptosis in these cells. To investigate the subcellular
distribution of HGyV-Apoptin, which also contains putative
nuclear localisation and export signals (Figure 1a), as well as
morphological changes caused by its expression, cells were
transfected with different Apoptin constructs and analysed by
fluorescence microscopy. Imaging of HCT116 colon carci-
noma cells transfected with pCAV-GFP-AP or pHGyV-GFP-
AP at 24 and 48 h post transfection revealed a similar
Figure 1 Expression of CAV- and HGyV-Apoptin in cancer cells. (a) Alignment of the protein sequence of CAV-Apoptin (NP_056774.1) and HGyV-Apoptin (CBZ41794.1)
using computer software Align (http://xylian.igh.cnrs.fr/bin/align-guess.cgi). Important functional domains, including LRS (leucine-rich domain), NLS1/2 and NES are indicated
by boxes and the predicted phosphorylation sites threonine 108 or threonine 111 are indicated by black arrows. Whole cell lysates of HCT116 colon carcinoma (b) and Saos-2
osteosarcoma (c) cells transfected with the indicated plasmids were prepared and western blot analysis for detection of GFP- or FLAG-Apoptin, respectively, as well as b-Actin
as a loading control was performed. Molecular weights of the bands are indicated with arrows and blots were cut and combined at the black line
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expression pattern of CAV- and HGyV-Apoptin (Figure 2a).
CAV-Apoptin has been shown to initially exhibit a fine
granular distribution within the nucleus, later clustering to
form aggregates, at which point the cell becomes apoptotic.
This characteristic morphology was also observed with
HGyV-Apoptin in transfected Saos-2 osteosarcoma cells
after 2 and 5 days, respectively (Figure 2b). To exclude a
potential promoting effect of the GFP-tag on nuclear trans-
location Saos-2 cells were transfected with FLAG-CAV-AP or
FLAG-HGyV-AP. Subsequent indirect immunofluorescence
to detect FLAG-Apoptin revealed the same expression
pattern as observed for GFP-Apoptin (Figure 2c). Similar
cellular distribution was observed in the HT1080 breast
cancer cell line (data not shown).
HGyV-GFP-Apoptin induces cell death in Saos-2 osteo-
sarcoma cells. To examine the cytotoxic function of HGyV-
GFP-AP Saos-2 human osteosarcoma cells were transfected
by nucleofection with pHGyV-GFP-AP, pCAV-GFP-AP or the
corresponding pEGFP-C1 control vector. Apoptosis was
quantified by flow cytometric analysis as percentage of
Annexin-V-positive cells among the transfected cells after
Annexin-V-APC/ propidium iodide (PI) staining. After 5 days
between 40 and 50% of cells expressing GFP-Apoptin were
apoptotic compared with only 5% apoptotic cells in those
transfected with pEGFP-C1 (Figure 3a). The level of cell
death induced by HGyV-Apoptin was similar to the level
achieved by CAV-Apoptin.
Furthermore, a colony-forming assay of HT1080 cells
comparably transfected with pEGFP-C1 or pHGyV-GFP-AP
showed very few HGyV-GFP-AP expressing cells, whereas
the control pEGFP-C1 transfected cells were able to form
countless colonies in the presence of G418 (data not shown)
indicating a cytotoxic effect of HGyV-GFP-AP.
To compare the pro-apoptotic effect of GFP- and FLAG-
tagged Apoptin, Saos-2 cells were transfected with different
Apoptin and control plasmids. After 5 days cells were fixed,
stained with anti-FLAG antibody (for pCAV-FLAG-AP and
pHGyV-FLAG-AP) and counterstained with DAPI for the
detection of nuclear morphology. Apoptosis was quantified by
scoring cells expressing either GFP- or FLAG-Apoptin and
displaying clear apoptotic nuclear morphology. Results
suggested that both CAV- and HGyV-Apoptin efficiently
induce apoptosis as compared with the pEGFP-C1 control.
Furthermore, no significant differences between the GFP- or
FLAG-tagged Apoptin could be observed (Figure 3c).
HGyV-GFP-Apoptin is expressed in the cytoplasm of
normal human fibroblasts and translocates to the
nucleus of transformed counterparts. One of the
Figure 2 Nuclear translocation of GFP- and FLAG-Apoptin in cancer cells. HCT116 (a) and Saos-2 (b) cancer cells were transfected with pCAV-GFP-AP or pHGyV-GFP-
AP and the corresponding pEGFP-C1 control plasmid. Cells were directly imaged in culture dishes after 1 or 2 days (a) or fixed and counterstained with DAPI at 2 and 5 days
post-transfection (b) as indicated. Saos-2 cells (c) transfected with pCAV-FLAG-AP or pHGyV-FLAG-AP were fixed after 5 days and stained with a primary mouse anti-FLAG
and secondary FITC anti-mouse antibody for detection of FLAG-Apoptin. Nuclei were detected by counterstaining with DAPI. Arrows indicate apoptotic nuclei
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important characteristics of CAV-Apoptin is its distinct tumour
specific nuclear localisation, which is necessary for its ability
to selectively induce apoptosis in transformed but not in
normal cells. To investigate whether HGyV-Apoptin shows
the same tumour selectivity pEGFP-C1, pHGyV-GFP-AP,
pCAV-GFP-AP, pHGyV-FLAG-AP and pCAV-FLAG-AP
were transfected into 1BR3 normal human fibroblasts
and their SV40-LT transformed counterparts, (1BR3LT).
After 3 days cells were counterstained with DAPI and
analysed by fluorescent microscopy to quantify apoptosis
by scoring the GFP-positive cells containing condensed
or fragmented nuclei. The normal 1BR3 fibroblasts exhib-
ited a marked difference in cellular localisation of both
CAV-GFP-AP and HGyV-GFP-AP as compared with trans-
formed 1BR3LT (Figure 4a). In normal cells, HGyV- and
CAV-GFP-Apoptin were mainly expressed in the cytoplasm,
while in the transformed cells both CAV- and HGyV-GFP-
Apoptin had a predominantly nuclear localisation. Similarly,
FLAG-tagged CAV- or HGyV-Apoptin was localised to the
nucleus of transformed 1BR3LT cells, whereas it was
predominantly cytoplasmic in normal 1BR3 fibroblasts
(data not shown). This difference in subcellular localisation
was associated with increased apoptosis in the trans-
formed cells transduced with either FLAG- or GFP-Apoptin
(Figure 4b).
Discussion
Tumour specificity remains one of the main hurdles for
successful treatment of cancer.20 A number of viral and
Figure 3 Induction of cell death in Saos-2 cells at 5 days after transfection. Saos-2 cells were transfected by nucleofection with pCAV-GFP-AP, pHGyV-GFP-AP or the
corresponding pEGFP-C1 control plasmid, as well as pCAV-FLAG-AP and pHGyV-FLAG-AP. Cell death was measured by flow cytometric analysis after Annexin-V-APC/ PI
staining. (a) Quantification of cell death as % of APC-labelled cells in the GFP-positive population after 5 days (*Po0.01). Error bars indicate standard deviation of three
experiments. (b) Corresponding FACS dot plots of Annexin-V-APC (x-axis) versus PI (y-axis) obtained after 2 and 5 days. (c) After 5 days transfected Saos-2 cells were fixed,
stained with a primary mouse anti-FLAG and secondary FITC anti-mouse antibody (for pCAV-FLAG-AP and pHGyV-FLAG-AP) and counterstained with DAPI for the detection
of nuclear morphology. Cell death was quantified as the percentage of GFP- or FLAG-positive cells showing condensed or fragmented nuclei. Error bars indicate standard
deviation of two independent experiments
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cellular proteins have been described that show tumour-
specific toxicity, including Apoptin, Trail, mda-7 (etc).21 The
therapeutic potential of such proteins and their cellular targets
is of immense interest. Recently, a HGyV has been identified
encoding a viral protein resembling the CAV-derived Apoptin.
Here we provide clear evidence that this HGyV-Apoptin
shows a tumour-specific nuclear expression pattern as has
been described previously for CAV-Apoptin to be important for
its cytotoxicity.7 Furthermore, expression of HGyV-Apoptin
resulted in the induction of apoptosis in transformed cells but
not in the normal human cell line 1BR3. However, further
studies, including the use of different types of normal cells,
are necessary to confirm that HGyV-Apoptin has tumour-
selective cytotoxicity and could thus provide a novel tool for
cancer treatment.
Many studies in the past decade have provided insight into
the mechanism of Apoptin-induced apoptosis. However, the
basis for its increased sensitivity for cancer cells remains
largely unclear. In addition to translocation to the nucleus,
CAV-Apoptin is phosphorylated on threonine 108 in cancer
cells but not in normal cells, which seems to be important for
enabling Apoptin to induce apoptosis.9 Several cellular kinases
have been proposed to be responsible for CAV-Apoptin
phosphorylation.14,18 We have recently identified PKCb to
be important for phosphorylation and activation of CAV-
Apoptin.17 It would be important to investigate whether HGyV-
Apoptin is phosphorylated in a similar manner by the kinases
which have been shown to interact with CAV-Apoptin. These
studies are currently on-going.
Although so far no link between this novel HGyV and any
human disease has been identified, the clear apoptotic activity
of its encoded protein HGyV-Apoptin offers an intriguing
opportunity to investigate its potential pathological role.
Furthermore a better understanding of the function of the
viral protein HGyV-Apoptin may reveal involvement in human
disease and lead to the development of novel therapeutics for
cancer.
Materials and Methods
Cell lines and cell culture. HCT116 human colorectal carcinoma cells were
obtained from ATCC (Manassas, VA, USA) and maintained in McCoy’s 5A medium
supplemented with 10% foetal bovine serum 40 U/ml Penicillin and 40 mg/ml
Streptomycin (all PAA Laboratories, Yeovil, UK). Saos-2 human osteosarcoma
cells were purchased from ATCC and grown in DMEM (PAA Laboratories) supple-
mented with 10% foetal bovine serum 40 U/ml Penicillin and 40mg/ml Streptomycin.
1BR3 normal and 1BR3 SV40 1BR3LT were a gift from Prof. Alan Lehmann (Sussex
Centre for Genome Damage and Stability, University of Sussex, UK) and maintained
Figure 4 Cytosolic expression of GFP-Apoptin and quantification of apoptosis in 1BR3 normal human fibroblasts. Normal (1BR3) and transformed (1BR3LT) human
fibroblast cell lines were transfected by nucleofection with pCAV-GFP-AP, pHGyV-GFP-AP or the corresponding pEGFP-C1 control plasmid as well as pCAV-FLAG-AP and
pHGyV-FLAG-AP. After 3 days cells were fixed and counterstained with DAPI to analyse the subcellular localisation of GFP-Apoptin. Expression of FLAG-AP was detected
using primary mouse anti-FLAG and secondary FITC anti-mouse antibody (a). Apoptosis was quantified by scoring GFP- or FLAG-positive cells containing condensed or
fragmented nuclei (b). Over one hundred transfected cells were analysed and experiments were repeated twice (error bars indicate standard deviation)
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in DMEM containing 15% foetal bovine serum 40 U/ml Penicillin and 40 mg/ml
Streptomycin. All cell lines were incubated at 37 1C and 5% CO2.
Generation of HGyV-Apoptin. A codon optimised HGyV-Apoptin gene
was constructed using primers overlapping by 15 bases (Table 1). FOR1
introduces a Kozak sequence upstream of the ATG start codon and a BamHI site
for subsequent cloning. REV5 introduces an EcoRI site for subsequent cloning.
Primers FOR1-5 and REV1-4 were mixed in equimolar amounts and heated to
95 0C for 2 min and cooled slowly to room temperature. Gaps were filled in with T4
DNA Polymerase for 15 min at 12 1C and finally the gaps were closed by treatment
with T4 DNA Ligase for 15 min at RT. The resulting product was PCR amplified
with primers FOR1 and REV5 and the PCR product was TOPO TA cloned
(Invitrogen Life Technologies, Paisley, UK).
Inserts were sequence verified and a correct HGyV-AP was removed from
the TOPO vector by BamHI/EcoRI digestion and cloned in-frame with GFP into
the BglII/EcoRI digested mammalian expression vector pEGFP-C1 (Clontech,
Saint-Germain-en-Laye, France) and named pHGyV-GFP-AP.
pHGyV-FLAG-AP was cloned by removing HGyV-AP from the TOPO vector by
EcoRI digestion and filling in with Klenow. p3X-FLAG (Sigma-Aldrich, Poole, UK)
was digested with BamHI and EcoRI, blunt ended with Mungbean nuclease and
phosphates were removed by calf intestinal phosphatase treatment. Vector and
insert were blunt end ligated and the correct orientation was determined by BstXI
and BamHI digestion. Plasmids containing an insert in the correct orientation were
sequence verified.
Plasmids and transient transfection. Expression vectors for HGyV-
Apoptin (pHGyV-GFP-AP, pHGyV-FLAG-AP) were constructed as part of this
study. pCAV-GFP-AP was generated as described previously10 and pCAV-FLAG-
AP was received from Dr. Jose Teodoro (Goodman Cancer Research Centre,
Montreal, QC, Canada). Other control vectors used were pcDNA3.1 (Invitrogen)
and pEGFP-C1.
HCT116 cells were transiently transfected using X-tremeGENE HP transfection
reagent according to the manufacturer’s protocol (Roche Diagnostics, Burgess
Hill, UK). Transfection of Saos-2 and 1BR3/1BR3LT cells was achieved using
Nucleofector technology as recommended by the manufacturer (Lonza, Basel,
Switzerland).
Flow cytometric analysis. Cells were seeded on 12-well plates and
collected at 2 or 5 days after nucleofection. Apoptosis was quantified by staining
with Annexin-V-APC (Invitrogen) and PI (Sigma) and subsequent analysis on a BD
FACSCanto II (Becton Dickinson, Oxford, UK). Data was analysed using FlowJo
software (Tree Star, Inc., Ashland, OR, USA).
Western blot analysis. Protein extracts were prepared by washing cells and
directly lysing them in Laemmli sample buffer (62.5 mM Tris-HCl pH 6.7, 100 mm
b-mercaptoethanol, 2% SDS, 1mg/ml aprotinin, 1mg/ml leupeptin, 100mg/ml
phenylmethylsulphoxide). SDS-PAGE was performed and proteins were
transferred to nitrocellulose membranes (Sigma). Membranes were incubated
with specific primary and secondary antibodies as indicated and developed using
a home-made enhanced chemiluminescent system. The antibodies used were:
rabbit anti-GFP (Cell Signaling, Beverly, MA, USA), mouse anti-FLAG (Sigma),
mouse anti-b-Actin (Sigma) and secondary anti-mouse (Sigma) or anti-rabbit
(GE Healthcare, Chalfont St. Giles, UK) linked to horseradish peroxidase.
Fluorescence microscopy. HCT116 cells were imaged directly on culture
plates at 1 or 2 days post-transfection using an Olympus CKX41 inverted
microscope (Southend-on-Sea, UK).
Saos-2 and 1BR3/1BR3LT cells were transfected by nucleofection and grown on
8-well culture slides (Becton Dickinson). After 3 or 5 days cells were washed once
with PBS, fixed in 2% paraformaldehyde for 30 min at 37 1C and permeabilized with
0.2% Triton X-100 for 20 min. For the detection of FLAG tag cells were washed in
PBS, blocked using 3% BSA in PBS-T for 30 min at 37 1C and incubated with the
primary anti-FLAG antibody and the secondary antibody anti-mouse-FITC (both
Sigma) for 2 h or 1 h, respectively, at 37 1C with washing steps in PBS between the
incubations. All cells were mounted in Vectashield mounting medium containing
DAPI (Vector Laboratories, Peterborough, UK) for nuclear staining and images were
acquired using an Olympus BX61 automated fluorescence microscope.
Apoptosis was quantified by scoring the GFP-positive cells containing condensed
or fragmented nuclei. Over one hundred transfected cells were analysed and
experiments were repeated twice.
Statistical analysis. A paired two-tailed Student’s t-test was used to
calculate significance.
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